A neutral overall trial result seems to be due to harms in patients with cerebral ischemia and benefits in those with ...

Patients with diffuse disease are less likely to see improvements in flow, data from the PPG Global Registry show.

While the AI did fine on multiple-choice questions and could justify its answers, it failed a retest just 2 weeks later.

The results, which show fewer false positives with the Fetal Medicine Foundation’s model, could promote better prevention.

Some cautioned against reading too much into this analysis, since the main trial did not meet its primary endpoint.

One expert urged caution, saying, “Sometimes this smells like expanding the market” in the absence of high-quality RCT data.

The Evolut valves posed difficulties for operators trying to access the coronaries, a potential problem for younger patients.

The dedicated device can lacerate bioprosthetic leaflets poised to cause coronary obstruction—and does it quickly.

The simple tool includes just three factors, making it easy to use by the nonclinical staff most likely to use it.

The first trial to test shortened DAPT in coronary DCBs, REC-CAGEFREE II builds upon the evidence available for DES PCI.

Researchers saw some differences between valve types; while provocative, these data need confirmation, observers say.

Interventionalists were stunned by the results—a clear win for PCI/TAVI—but surgeons argued the devil is in the details.